1.40
7.69%
0.10
Rani Therapeutics Holdings Inc Borsa (RANI) Ultime notizie
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $11.71 Average PT from Brokerages - MarketBeat
Rani Therapeutics stock hits 52-week low at $1.32 - Investing.com
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Insider Kate Mckinley Acquires 17,960 Shares - MarketBeat
Rani Therapeutics stock hits 52-week low at $1.85 By Investing.com - Investing.com Nigeria
Rani Therapeutics stock hits 52-week low at $1.85 - Investing.com India
Rani Therapeutics stock hits 52-week low at $1.94 By Investing.com - Investing.com Nigeria
Rani Therapeutics stock hits 52-week low at $1.94 - Investing.com India
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $11.71 Average Target Price from Analysts - Defense World
Brokerages Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Price Target at $11.71 - MarketBeat
What is Zacks Small Cap’s Forecast for RANI FY2024 Earnings? - Defense World
What is Zacks Small Cap's Forecast for RANI FY2024 Earnings? - MarketBeat
RANI: Third Quarter Update - MSN
Rani Therapeutics' (RANI) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Rani Therapeutics Advances in Biotherapeutics Market - TipRanks
Rani Therapeutics Holdings Inc (RANI) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires New Stake in Rani Therapeutics H - GuruFocus.com
Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update - The Manila Times
Rani Therapeutics Slashes Q3 Loss by 31%, Secures $20M Funding for GLP-1 Development | RANI Stock News - StockTitan
Rani Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Brokerages Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) PT at $11.71 - Defense World
Analysts Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Target Price at $11.71 - MarketBeat
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Sees Significant Growth in Short Interest - MarketBeat
Allied Gaming & Entertainment And 2 Other US Penny Stocks To Watch - Simply Wall St
RANI: New Triagonist Data in Weight Loss - Zacks Small Cap Research
Rani Therapeutics shares hold buy rating on positive preclinical data By Investing.com - Investing.com Australia
Rani Therapeutics stock gets positive outlook from H.C. Wainwright after novel obesity candidate progress - Investing.com Australia
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.75% - MSN
Rani Therapeutics shares hold buy rating on positive preclinical data - Investing.com
Rani Therapeutics (NASDAQ:RANI) Receives "Buy" Rating from HC Wainwright - MarketBeat
Rani Therapeutics reports promising obesity treatment delivery By Investing.com - Investing.com South Africa
Rani therapeutics sees $10 million in stock sales by major investors By Investing.com - Investing.com
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Major Shareholder South Cone Investments Limited Sells 3,829,360 Shares - MarketBeat
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.75% - MSN
Rani Therapeutics reports promising obesity treatment delivery - Investing.com
Rani Therapeutics Announces New Preclinical Pharmacokinetic - GlobeNewswire
Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist - The Manila Times
Rani Therapeutics (RANI) Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist - StreetInsider.com
Rani Therapeutics to sell 3M shares at $3.00 in registered direct offering - MSN
Recent Insider Activity Could Benefit Comcast Corp (CMCSA) - Knox Daily
Market Momentum: Rani Therapeutics Holdings Inc (RANI) Registers a -33.33 Decrease, Closing at 2.12 - The Dwinnex
There is no doubt that Rani Therapeutics Holdings Inc (RANI) ticks all the boxes. - SETE News
An Analysis of Avidity Biosciences Inc (RNA)’s Potential Price Growth - Knox Daily
Form 424B5 Rani Therapeutics Holdin - StreetInsider.com
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):